Fibralign produces therapeutic medical devices targeted at unmet needs in regenerative medicine, using its patented Nanoweave® 3D scaffolding technology.
Its first product, BioBridge®, is a thread-like device designed to treat patients suffering from secondary lymphedema. The World Health Organization estimates that over 15 million people suffer from cancer-related lymphedema. This chronic disease currently has no cure and causes long-term physical, psychological, and social problems for patients, significantly impacting quality of life. While this represents a unique and significant initial market, BioBridge has significant follow on product opportunities for treating ischemia, cell/drug delivery and gene therapy (mmRNA).
BioBridge has received 510(k) clearance. The Company is starting a clinical study for breast cancer related lymphedema with Stanford University to expand indication of use and preparing for CE mark.
Fibralign won the 2014 Medtech Innovator award, placing first out of 267 startups.